Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016

Surveillance Summaries / March 27, 2020 / 69(4);1–12

Print
Related Pages

Please note:. This report has been corrected. An erratum has been published..

Matthew J. Maenner, PhD1; Kelly A. Shaw, PhD1; Jon Baio; EdS1; Anita Washington, MPH1; Mary Patrick, MPH1; Monica DiRienzo, MA1; Deborah L. Christensen, PhD1; Lisa D. Wiggins, PhD1; Sydney Pettygrove, PhD2; Jennifer G. Andrews, PhD2; Maya Lopez, MD3; Allison Hudson3; Thaer Baroud, MHSA, MA3; Yvette Schwenk3; Tiffany White, PhD4; Cordelia Robinson Rosenberg, PhD5; Li-Ching Lee, PhD6; Rebecca A Harrington, PhD6; Margaret Huston6; Amy Hewitt, PhD-7; Amy Esler, PhD7; Jennifer Hall-Lande, PhD7; Jenny N. Poynter, PhD7; Libby Hallas-Muchow, MS7; John N. Constantino, MD8; Robert T. Fitzgerald, PhD8; Walter Zahorodny, PhD9; Josephine Shenouda, MS9; Julie L. Daniels, PhD10; Zachary Warren, PhD11; Alison Vehorn, MS11; Angelica Salinas, MS12, Maureen S. Durkin, DrPH, PhD12; Patricia M. Dietz, DrPH1 (View author affiliations)

View suggested citation
Article Metrics
Altmetric:
Citations:
Views:

Views equals page views plus PDF downloads

Metric Details
On This Page
Figures

Figure 1

Figure 2

Figure 3

Tables

Table 1

Table 2

Table 3

Table 4

Table 5

Related Materials

Abstract

Problem/Condition: Autism spectrum disorder (ASD).

Period Covered: 2016.

Description of System: The Autism and Developmental Disabilities Monitoring (ADDM) Network is an active surveillance program that provides estimates of the prevalence of ASD among children aged 8 years whose parents or guardians live in 11 ADDM Network sites in the United States (Arizona, Arkansas, Colorado, Georgia, Maryland, Minnesota, Missouri, New Jersey, North Carolina, Tennessee, and Wisconsin). Surveillance is conducted in two phases. The first phase involves review and abstraction of comprehensive evaluations that were completed by medical and educational service providers in the community. In the second phase, experienced clinicians who systematically review all abstracted information determine ASD case status. The case definition is based on ASD criteria described in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.

Results: For 2016, across all 11 sites, ASD prevalence was 18.5 per 1,000 (one in 54) children aged 8 years, and ASD was 4.3 times as prevalent among boys as among girls. ASD prevalence varied by site, ranging from 13.1 (Colorado) to 31.4 (New Jersey). Prevalence estimates were approximately identical for non-Hispanic white (white), non-Hispanic black (black), and Asian/Pacific Islander children (18.5, 18.3, and 17.9, respectively) but lower for Hispanic children (15.4). Among children with ASD for whom data on intellectual or cognitive functioning were available, 33% were classified as having intellectual disability (intelligence quotient [IQ] ≤70); this percentage was higher among girls than boys (39% versus 32%) and among black and Hispanic than white children (47%, 36%, and 27%, respectively). Black children with ASD were less likely to have a first evaluation by age 36 months than were white children with ASD (40% versus 45%). The overall median age at earliest known ASD diagnosis (51 months) was similar by sex and racial and ethnic groups; however, black children with IQ ≤70 had a later median age at ASD diagnosis than white children with IQ ≤70 (48 months versus 42 months).

Interpretation: The prevalence of ASD varied considerably across sites and was higher than previous estimates since 2014. Although no overall difference in ASD prevalence between black and white children aged 8 years was observed, the disparities for black children persisted in early evaluation and diagnosis of ASD. Hispanic children also continue to be identified as having ASD less frequently than white or black children.

Public Health Action: These findings highlight the variability in the evaluation and detection of ASD across communities and between sociodemographic groups. Continued efforts are needed for early and equitable identification of ASD and timely enrollment in services.

Top

Introduction

Autism spectrum disorder (ASD) is a developmental disability characterized by persistent impairments in social interaction and the presence of restricted, repetitive patterns of behaviors, interests, or activities (1). CDC has been tracking the prevalence of ASD since 1996, beginning with children in metropolitan Atlanta, Georgia (2). Subsequently, CDC established the Autism and Developmental Disabilities Monitoring (ADDM) Network, which has reported ASD prevalence in multiple communities in even-numbered years since 2000.

The previous ADDM Network ASD prevalence estimate was 16.8 per 1,000 (one in 59) children aged 8 years in 2014 (3). This is approximately 2.5 times higher than the first ADDM Network ASD prevalence estimates of 6.7 (one in 150) from 2000 and 2002 (4–7). Findings from each surveillance year between 2000 and 2014 have included variability and disparities in the prevalence of ASD (3–5,8–11). In contrast to other developmental disabilities (12–15), the ADDM Network reported higher ASD prevalence among more socioeconomically advantaged groups and among children classified as non-Hispanic white (white) than among other groups (16,17). Overall, the magnitude of prevalence differences by race and ethnicity has declined in recent years (3,17). Reduction of these disparities might indicate progress toward enhanced detection of ASD among all children.

Timely evaluation and identification of ASD among young children continue to be important public health goals (18,19) because evidence links early treatment and services for ASD with improved outcomes (20–23). Although greater numbers of children are identified as having ASD over time, previous ADDM Network findings suggest little overall change in the median age at ASD diagnosis (range: 50–56 months), and fewer than half of children with ASD had a record of a developmental evaluation by age 36 months (3–5,8–11). However, considerable variability has been reported between communities in both ASD prevalence and the ages at which ASD is diagnosed.

This report provides the latest available data on ASD prevalence among children aged 8 years living in ADDM Network sites in 2016, including variations in prevalence by site and demographic characteristics, median ages when children are evaluated and ASD is diagnosed, and co-occurrence of intellectual disability. Pediatric health care providers, educators, researchers, service providers, and policymakers can use these data to anticipate service needs in their communities and help develop policies that ensure early and comprehensive identification of ASD.

Top

Methods

Surveillance Sites and Procedures

The ADDM Network was composed of 11 sites for surveillance year 2016 (Arizona, Arkansas, Colorado, Georgia, Maryland, Minnesota, Missouri, New Jersey, North Carolina, Tennessee, and Wisconsin). Children included in ADDM surveillance year 2016 were born in 2008 and had a parent or guardian who lived in one of 11 surveillance sites in 2016. Each site selected a portion of its state (except Arkansas, which included the entire state) to monitor ASD among children aged 8 years in 2016. All sites functioned as public health authorities under the Health Insurance Portability and Accountability Act of 1996 Privacy Rule and met applicable local institutional review board, privacy, and confidentiality requirements under 45 CFR 46 (24). The racial and ethnic composition of populations in ADDM Network sites is provided (Supplementary Table 1, https://stacks.cdc.gov/view/cdc/85386).

Case Ascertainment and Surveillance Case Definition

The ADDM Network uses a multiple-source, records-based surveillance methodology developed by CDC’s Metropolitan Atlanta Developmental Disabilities Surveillance Program (2,24). The ADDM Network ASD surveillance methodology is a two-phase process that has been described previously (3). In brief, in the first phase, ADDM Network staff review records from medical, education, and service providers (e.g., autism specialty clinics or intervention providers) in the community after requesting records that include various billing codes from the International Classification of Disease, Ninth Revision (ICD-9) or International Classification of Diseases, Tenth Revision (ICD-10) or special education exceptionalities (Supplementary Table 2, https://stacks.cdc.gov/view/cdc/85386). If any record contains an indication of ASD, the child’s evaluations and other information (e.g., intelligence quotient [IQ] tests) are abstracted and compiled from all available sources in the community. Although all ADDM Network sites use records from medical and service providers, not all sites have complete access to education records.

In the second phase, an ADDM Network clinician reviews the deidentified, compiled record for each child to determine ASD case status. The ADDM Network ASD case definition is based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and the process for scoring the features of the surveillance case definition have been described previously (3,25,26). ADDM Network clinicians might assign ASD case status if documented evidence satisfies the behavioral criteria for the ASD case definition, or if the child has an established ASD diagnosis. ADDM Network clinicians might decide a child who otherwise meets ASD surveillance criteria should not be included as a case because of insufficient or conflicting information or if other conditions better account for the child’s symptoms. Another clinician performs a secondary review if the first reviewer indicates uncertainty. To monitor interrater reliability, 10% of records were randomly selected for an independent review (ASD case status kappa = 0.89) (Supplementary Table 3, https://stacks.cdc.gov/view/cdc/85386). At most ADDM Network sites, clinicians also applied the previous ASD case definition based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) for at least a portion of the children with abstracted information.

Additional Data Sources and Variable Definitions

Population denominators were obtained from the National Center for Health Statistics vintage 2018 bridged-race postcensal population estimates for 2016 (27). For study areas comprising subcounty school districts, a standardization process using public school enrollment counts was used to adjust the population estimates (Supplementary Methods, https://stacks.cdc.gov/view/cdc/85386). Each site linked each child to birth certificate information from their state. When successful, this linkage indicates which children were born in the state that they lived in at age 8 years and provides additional demographic information. Information about race and ethnicity came from information abstracted from the medical or education records, which was augmented by data from birth certificates and data from administrative or billing information. Children with race coded as “other” or “multiracial” were excluded from race-specific estimates, as were American Indian/Alaskan Native children because of small numbers.

Age at first developmental evaluation on record was based on each child’s abstracted evaluation information and restricted to children born in the state (or ADDM Network surveillance area in Minnesota) where the ADDM Network site is located. Age at first ASD diagnosis was based on the age of a child when an examiner recorded an ASD diagnostic statement or noted the child’s age when another provider previously diagnosed ASD. Intellectual disability status was based on IQ scores ≤70 on a child’s most recent test available through 2016. A child without an IQ score also could be classified as having intellectual disability on the basis of an examiner’s statement of intellectual disability in a developmental evaluation. Children were considered to have community-identified ASD if their records contained any of the following: 1) a diagnostic statement from a qualified professional of autistic disorder, pervasive developmental disorder not otherwise specified (PDD-NOS), Asperger disorder, or ASD; 2) any ASD ICD billing code at any time from birth through 2016; or 3) receipt of (or met eligibility for) special education services under the autism classification in public school.

Analytic Methods

Prevalence was calculated as the number of children with ASD per 1,000 children aged 8 years in the defined population or subgroup. Overall prevalence estimates included all children identified with ASD. Results for the combined (overall) total include data from all sites unless otherwise noted. Ninety-five percent confidence intervals (CIs) for prevalence, proportions, and prevalence ratios were calculated using the Wilson score method. Pearson chi-square tests were performed for comparison of proportions, and the Mantel-Haenszel (Woolf) test of homogeneity was used to compare prevalence ratios across sites. Permutation tests were conducted to test differences in medians. Statistical tests with p values <0.05 were considered statistically significant, as were 95% CIs that excluded 1.0 for prevalence ratios. Cumulative incidence of ASD diagnoses was calculated as the total children with ASD diagnosed during or before a given month of age, divided by the total population of children aged 8 years in the surveillance area. R software (version 3.5.3; R Foundation) and additional packages were used to conduct analyses. Additional information about the statistical software is available (Supplementary Table 4, https://stacks.cdc.gov/view/cdc/85386).

Top

Results

ASD Prevalence

The combined ASD prevalence, with data from all 11 sites, was 18.5 per 1,000 (one in 54) children aged 8 years. ASD prevalence ranged from 13.1 per 1,000 children aged 8 years (one in 76) in Colorado to 31.4 per 1,000 children aged 8 years (one in 32) in New Jersey (Table 1). The estimate for New Jersey was higher than for every other ADDM Network site. Two sites with limited or no access to education records had the lowest ASD prevalence estimates (Colorado [13.1] and Missouri [13.6]). ASD prevalence among boys was higher than among girls (29.7 versus 6.9). The combined male-to-female prevalence ratio was 4.3:1; site-specific ratios ranged from 3.4:1 to 4.7:1, with little evidence of heterogeneity by site.

Comparisons between surveillance years 2014 and 2016 are available (Supplementary Table 5, https://stacks.cdc.gov/view/cdc/85386). Among five sites that used the DSM-5–based case definition within the same geographic areas in 2014 and 2016, Maryland and Tennessee reported similar ASD prevalence in both years, whereas Arkansas, New Jersey, and Wisconsin reported increases. In the subset of children whose records also were reviewed using ADDM Network DSM-IV-TR ASD criteria, the DSM-IV-TR criteria classified 2% more ASD cases than DSM-5 criteria (Supplementary Table 6, https://stacks.cdc.gov/view/cdc/85386).

Overall ASD prevalence per 1,000 children aged 8 years was similar among white and non-Hispanic black (black) children (18.5 and 18.3, respectively) (Table 2). The white-to-black ASD prevalence ratio for the combined ADDM Network was 1.0; however, the prevalence ratio for white to black children was >1.0 in two ADDM Network sites (Arkansas and New Jersey). ASD prevalence among Asian/Pacific Islander children was 17.9 and similar to that among white and black children. ASD prevalence among Hispanic children was 15.4, which was lower than the prevalence among white and black children (white-to-Hispanic prevalence ratio and black-to-Hispanic prevalence ratio: 1.2). Numerator and denominator counts by race and ethnicity are available (Supplementary Table 7, https://stacks.cdc.gov/view/cdc/85386).

Co-Occurring Intellectual Disability

Ten of the 11 ADDM Network sites collected information on intellectual functioning for at least 60% of children meeting the ASD case definition (range: 65% [Maryland and Wisconsin] to 96% [Arkansas]). Similar proportions of cases among boys and girls had information on intellectual ability (80% versus 78%), as did white and black children (81% versus 79%). Across states, greater absolute variability was reported in the prevalence of ASD without intellectual disability than ASD with intellectual disability at the 10 sites (Figure 1).

Among children meeting ASD case status who had IQ information, 33% were classified as having intellectual disability (IQ ≤70) at their most recent test or examination, 24% had an IQ in the borderline range (IQ 71–85), and 42% had an IQ in the average or higher range (IQ >85) (Table 3). The percentage of children with co-occurring intellectual disability varied by site (range: 25% [New Jersey] to 42% [Georgia]). Overall, a higher percentage of girls than boys was classified as having intellectual disability (40% versus 32%), and black and Hispanic children were more likely than white children to be classified as having intellectual disability (47%, 36%, and 27%, respectively) (Supplementary Figures, https://stacks.cdc.gov/view/cdc/85386).

Age at First Evaluation and ASD Diagnosis

Among 3,981 children aged 8 years with ASD who were born in the state of residence, 44% were evaluated by age 36 months, with wide variation across ADDM Network sites (range: 33% [Arkansas] to 62% [North Carolina]) (Table 4). The median age at first evaluation ranged from 29 months (North Carolina) to 46 months (Arkansas). A higher percentage of girls was evaluated by age 36 months than boys (48% versus 43%) (Table 4). The majority of children with ASD and IQ ≤70 (58%) were evaluated by age 36 months, compared with 38% of children with IQ >70. The percentage of children with ASD evaluated by age 36 months varied by race and ethnicity: 45% among white children, 43% among Hispanic children, and 40% among black children.

Of the 5,108 children with ASD, 3,764 (74%) had an evaluation containing a statement of a clinical ASD diagnosis. Among those 3,764 children, the median age at ASD diagnosis was 51 months (range: 38 months [North Carolina] to 57 months [Arizona]) (Table 5). Children with ASD and IQ ≤70 had a median age at diagnosis of 44 months, whereas children with IQ >70 had a median age at diagnosis of 57 months. Among children with ASD and IQ ≤70, black children had an older median age at diagnosis than white children (48 versus 42 months). The cumulative incidence of ASD diagnoses indicates that community providers in New Jersey diagnosed more ASD cases by age 3 years than any other ADDM Network site, although the median age at diagnosis in New Jersey was the same as that of the overall ADDM Network (51 months) (Figure 2). The overall cumulative incidence of ASD diagnoses was 13.2 per 1,000 children by the time they turned age 8 years.

Comparison with Prevalence of Community-Identified ASD

In addition to ASD diagnoses written in developmental evaluations, many children received an ASD classification in school (Supplementary Table 8, https://stacks.cdc.gov/view/cdc/85386), and certain children’s medical records contained ICD billing codes indicating ASD. The prevalence of all children with an ASD diagnosis, education classification, or ICD code was 17.2 per 1,000 children aged 8 years, approximately 7% lower than the ADDM Network estimate of 18.5 per 1,000 children aged 8 years (Figure 3). Although community-identified ASD prevalence was similar to ASD prevalence on the basis of the ADDM Network case definition, ADDM sites with higher prevalence also ascertained more children without an ASD diagnosis.

Top

Discussion

The latest ASD prevalence estimate, as measured by the ADDM Network, is 18.5 per 1,000 children aged 8 years in 2016. This is approximately 10% higher than the 16.8 prevalence estimate the ADDM Network reported in 2014 (3) and approximately 175% higher than (2.8 times) the first estimates reported by the ADDM Network in 2000 and 2002 (4,5). These changes could reflect differences in community practices for identifying ASD, changes in the data available to the surveillance system, or other unknown factors.

As with previous reports, observed ASD prevalence varies among ADDM Network sites. Community-level differences related to ASD diagnosis or classification for services correlate with ASD prevalence estimates; ASD prevalence and rank order of estimates across sites were similar to the prevalence of community-identified ASD. Previous analyses from the ADDM Network have shown a positive association between neighborhood socioeconomic status (SES) and ASD prevalence, which suggests ASD might be more readily identified in high-SES communities or among populations with good access to services (16). In this sense, the ADDM Network prevalence estimates could be used to support efforts to improve ASD diagnosis for lower-SES groups in the community.

Timely Evaluations and Age at First ASD Diagnosis

For the first time since ADDM began, no statistically significant difference was found in the overall ASD prevalence among black and white children. This diminishing disparity in ASD prevalence might signify progress toward earlier and more equitable identification of ASD. Although black children with ASD were more likely than white children to have an intellectual disability and children with intellectual disability were more likely to be evaluated early, black children were still less likely than white children to be evaluated by age 36 months. In addition, among children with intellectual disability, the median age at ASD diagnosis was 6 months later for black than for white children. Further study is needed to identify community-level barriers to timely evaluation and diagnosis of ASD so that treatments can be delivered as early as possible. Examining differences between communities with earlier and later ASD identification might reveal successful practices or policies that could be implemented in other communities. CDC’s “Learn the Signs. Act Early.” initiative works with Act Early Ambassadors who support state and territorial or national efforts to improve early identification of developmental disabilities and promote the integration of developmental monitoring in systems that serve children and their families (https://www.cdc.gov/ncbddd/actearly).

Although early diagnosis of ASD is a major public health goal and one of the Healthy People 2020 objectives (https://www.healthypeople.gov/2020/default), the median age at first ASD diagnosis has changed little over the course of ADDM Network reporting. However, this metric might not fully capture community progress toward early identification and could mask improvement. For instance, the median age at ASD diagnosis will increase if the community begins diagnosing more ASD among children at older ages who in previous years would not have received an ASD diagnosis by age 8 years. An absolute metric, such as cumulative incidence, might reveal advances in early identification over previous cohorts, as shown in the Early ADDM Network report (28).

Comparison with Other Autism Data Systems

The National Survey of Children’s Health (NSCH) and the National Health Interview Survey (NHIS) are two U.S. nationally representative surveys that measure ASD prevalence by asking parents and caregivers if a doctor or health professional told them that their child has ASD. The 2016 NSCH and the 2015–2017 NHIS both estimated ASD prevalence at 25 per 1,000 children aged 3–17 years (13,29). Important differences exist between the national surveys and the ADDM Network that warrant consideration when comparing prevalence estimates. The surveys rely on parent-reported ASD diagnoses among children aged 3–17 years in a nationally representative sample, whereas the ADDM Network uses documented information from qualified professionals and monitors ASD among children aged 8 years in participating communities. These data sources might be used in complementary ways; for instance, most ADDM Network sites indicate lower ASD prevalence than the survey estimates, which might indicate a need for improved ASD identification in those communities. To facilitate comparisons between different data systems, CDC developed an interactive website that presents U.S. state-based ASD prevalence data from four data systems (ADDM Network, NSCH, Medicaid, and special education) (https://www.cdc.gov/ncbddd/autism/data/index.html).

ASD prevalence reports from other countries provide information about aspects of ASD that are not measured in the United States and allow for comparisons with the ADDM Network. In 2018, Canada released the first National Autism Surveillance System (NASS) report (30). NASS monitored ASD among 1.9 million children aged 5–17 years across all Canadian provinces in 2015 and relied on existing ASD diagnoses to ascertain cases. The overall ASD prevalence was 15.2 per 1,000 children with province estimates ranging from 8.0 to 17.5 per 1,000, which was slightly lower than estimates from the ADDM Network. NASS data indicated that 28% of children with ASD received the diagnosis after age 8 years. A study using linked registry data from Denmark revealed an even greater proportion of children with ASD diagnosed after age 8 years (31). Danish children born in 2008 had a cumulative incidence of diagnosed ASD of approximately 12 per 1,000 children by age 8 years (comparable to the cumulative incidence of ASD diagnoses among children aged 8 years in the ADDM Network) (Figure 2); among older Danish cohorts, cumulative incidence was as high as 28 per 1,000 by age 15–16 years.

Top

Limitations

The findings in this report are subject to at least four limitations. First, the ADDM Network methods rely on the quality and completeness of existing documents to ascertain cases. Sites without access to education records for large portions of their population might not be ascertaining children (particularly black or Hispanic children) (32) who only receive services for ASD at school. Second, record completeness is also important for documenting when ASD was first diagnosed in a child, whether the child had IQ testing, and when a child was first evaluated. Reduced access to records, incomplete records, or both, could lead to an underestimate of the number of children identified as having ASD. Third, sites participating in the ADDM Network are funded through a competitive process and are encouraged to include diverse communities; however, the resulting sites are not nationally representative and do not generate nationally representative ASD prevalence estimates. Finally, geographic coverage of the ADDM Network has changed over time, complicating interpretation of temporal trends.

Top

Future Directions

The ADDM Network will continue data collection for the 2018 and 2020 surveillance years. Sites in 11 states will monitor ASD prevalence among children aged 4 and 8 years. Five sites have initiated a new activity to describe outcomes for children aged 16 years who were initially ascertained by the ADDM Network at age 8 years. To provide the most comprehensive information on how communities identify, serve, and support persons with ASD, the ADDM Network increasingly will focus on community indicators of ASD identification, disparities in service use, and co-occurring conditions among persons with ASD.

Top

Conclusion

These findings from the 2016 ADDM Network indicate considerable variability in ASD prevalence across communities and higher ASD prevalence than previous estimates from the ADDM Network. For the first time, no overall difference in ASD prevalence between black and white children was reported, although disparities in early intervention and identification persist for black children. ASD prevalence among Hispanic children continues to be lower than among white or black children. Black and Hispanic children with ASD were evaluated at older ages than white children and were more likely to have intellectual disability. Black children with intellectual disability and ASD also received diagnoses at older ages than did white children with intellectual disability and ASD, which might limit opportunities to receive services that could improve their outcomes and quality of life. ASD continues to be a public health concern; the latest data from the ADDM Network underscore the ongoing need for timely and accessible developmental assessments, educational supports, and services for persons with ASD and their families.

Top

Acknowledgments

Project management, data collection, and abstraction: Kristen Clancy Mancilla, Arizona; Michelle Cantrell Kelley and Sandra Walker, Arkansas; MJ Erickson-Eger, Leanne Glenn, Julia Group, Leovi Madera, Jean Menconi, and Cynthia Vogel, Colorado; Kate Sidwell, Cindy Cruz Alvarez, Michael Verile, and Yuriy Levin, New Jersey; Julie Rusyniak, North Carolina; Madeline Santulli, Tennessee; Lynn Peterson, Lynn Boelter, Robert Rettammel, and Madison Carey, Wisconsin. Data management and programming support: Susan Williams, CDC; Julie Nick, Arkansas; Bill Vertees, Colorado; Adam Ryer, Maryland; Paul Zumoff, New Jersey; Carrie Arneson, Wisconsin. Clinician review activities: Stefanie Jernigan, Arkansas; Terry Hall, Patricia LaVesser, Judy Reaven, and Nuri Reyes, Colorado; Rebecca Born, Cassondra Gayman, Michael Morrier, Catherine Rice, and Daniel Wright, Georgia; Rebecca Born and Mary Schlaak, Maryland; Catherine Burrows, Minnesota; Carolyn Skowyra, Rebecca Born, and Michael Bunis, Missouri; Audrey Mars, Mildred Waale, Arline Fusco, Tara Gleeson, and Gail Burack, New Jersey; Jessica Rivers, Julie Rusyniak, and Tamara Watson, North Carolina; Evon Batey Lee, Amy Swanson, and Amy S. Weitlauf, Tennessee; Madison Carey, Mary Schlaak, and Maia Piccagli, Wisconsin. Project staff including data abstractors, epidemiologists, and others. Ongoing ADDM Network support: Bruce Heath, CDC.

Top

Corresponding author: Matthew J. Maenner, National Center on Birth Defects and Developmental Disabilities, CDC. Telephone: 404-498-3072; E-mail: mmaenner@cdc.gov.

Top

1National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, Georgia; 2University of Arizona, Tucson; 3University of Arkansas for Medical Sciences, Little Rock; 4Colorado Department of Public Health and Environment, Denver; 5University of Colorado School of Medicine, Department of Pediatrics, Aurora; 6Johns Hopkins University, Baltimore, Maryland; 7University of Minnesota, Minneapolis; 8Washington University in St. Louis, Missouri; 9Rutgers New Jersey Medical School, Newark; 10University of North Carolina, Chapel Hill; 11Vanderbilt University Medical Center, Nashville, Tennessee; 12University of Wisconsin, Madison

Top

Conflicts of Interest

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Zachary Warren reports personal fees from Hoffman La Roche, grants and personal fees from Adaptive Technology Consulting, grants from Autism Speaks, grants from Cognoa, and grants from Simons Foundation; all fees and grants received are outside the submitted work. John Constantino reports a grant from Western Psychological Services outside the submitted work.

Top

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
  2. Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. Prevalence of autism in a US metropolitan area. JAMA 2003;289:49–55. CrossRef PubMed
  3. Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2014. MMWR Surveill Summ 2018;67(No. SS-6). CrossRef PubMed
  4. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2000 Principal Investigators; CDC. Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, six sites, United States, 2000. MMWR Surveill Summ 2007;56(No. SS-1). PubMed
  5. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators; CDC. Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2002. MMWR Surveill Summ 2007;56(No. SS-1). PubMed
  6. Van Naarden Braun K, Christensen D, Doernberg N, et al. Trends in the prevalence of autism spectrum disorder, cerebral palsy, hearing loss, intellectual disability, and vision impairment, metropolitan Atlanta, 1991–2010. PLoS One 2015;10:e0124120. CrossRef PubMed
  7. Rice C, Nicholas J, Baio J, et al. Changes in autism spectrum disorder prevalence in 4 areas of the United States. Disabil Health J 2010;3:186–201. CrossRef PubMed
  8. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators; CDC. Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ 2009;58(No. SS-10). PubMed
  9. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; CDC. Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012;61(No. SS-3). PubMed
  10. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; CDC. Prevalence of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2010. MMWR Surveill Summ 2014;63(No. SS-2).
  11. Christensen DL, Baio J, Van Naarden Braun K, et al. CDC. Prevalence and characteristics of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2012. MMWR Surveill Summ 2016;65(No. SS-3). CrossRef PubMed
  12. Forthun I, Strandberg-Larsen K, Wilcox AJ, et al. Parental socioeconomic status and risk of cerebral palsy in the child: evidence from two Nordic population-based cohorts. Int J Epidemiol 2018;47:1298–306. CrossRef PubMed
  13. Zablotsky B, Black LI, Maenner MJ, et al. Prevalence and trends of developmental disabilities among children in the United States: 2009–2017. Pediatrics 2019;144:e20190811. CrossRef PubMed
  14. Durkin MS, Maenner MJ, Benedict RE, et al. The role of socio-economic status and perinatal factors in racial disparities in the risk of cerebral palsy. Dev Med Child Neurol 2015;57:835–43. CrossRef PubMed
  15. Maenner MJ, Blumberg SJ, Kogan MD, Christensen D, Yeargin-Allsopp M, Schieve LA. Prevalence of cerebral palsy and intellectual disability among children identified in two U.S. national surveys, 2011–2013. Ann Epidemiol 2016;26:222–6. CrossRef PubMed
  16. Durkin MS, Maenner MJ, Baio J, et al. Autism spectrum disorder among US children (2002–2010): socioeconomic, racial, and ethnic disparities. Am J Public Health 2017;107:1818–26. CrossRef PubMed
  17. Pedersen A, Pettygrove S, Meaney FJ, et al. Prevalence of autism spectrum disorders in Hispanic and non-Hispanic white children. Pediatrics 2012;129:e629–35. CrossRef PubMed
  18. Johnson CP, Myers SM; American Academy of Pediatrics Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007;120:1183–215. CrossRef
  19. US Department of Health and Human Services. Healthy people 2020. Washington, DC: US Department of Health and Human Services; 2010.
  20. Reichow B, Hume K, Barton EE, Boyd BA. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2018;5:CD009260. CrossRef PubMed
  21. Rogers SJ, Estes A, Lord C, et al. Effects of a brief Early Start Denver model (ESDM)-based parent intervention on toddlers at risk for autism spectrum disorders: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 2012;51:1052–65. CrossRef PubMed
  22. Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics 2010;125:e17–23. CrossRef PubMed
  23. Rogers SJ, Estes A, Lord C, et al. A multisite randomized controlled two-phase trial of the Early Start Denver Model compared to treatment as usual. J Am Acad Child Adolesc Psychiatry 2019;58:853–65. CrossRef
  24. Public Welfare, Protection of Human Subjects. C.F.R. 45 Part 46 (2010).
  25. Yeargin-Allsopp M, Murphy CC, Oakley GP, Sikes RK. A multiple-source method for studying the prevalence of developmental disabilities in children: the Metropolitan Atlanta Developmental Disabilities Study. Pediatrics 1992;89:624–30. PubMed
  26. Wiggins L, Christensen D, Van Naarden Braun K, Martin L, Baio J. Comparison of autism spectrum disorder surveillance status based on two different diagnostic schemes: findings from the Metropolitan Atlanta Developmental Disabilities Surveillance Program, 2012. PLoS One 2018;13:e0208079. CrossRef PubMed
  27. CDC. Vintage 2018 bridged-race postcensal population estimates for April 1, 2010, July 1, 2010–July 1, 2018, by year, county, single-year of age (0 to 85+ years), bridged-race, Hispanic origin, and sex. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https://www.cdc.gov/nchs/nvss/bridged_race.htm
  28. Shaw KA, Maenner MJ, Baio J, et al. Early identification of autism spectrum disorder among children aged 4 years—Early Autism and Developmental Disabilities Monitoring Network, six sites, United States, 2016. MMWR Surveill Summ 2020;69(No. SS-3).
  29. Kogan MD, Vladutiu CJ, Schieve LA, et al. The prevalence of parent-reported autism spectrum disorder among US children. Pediatrics 2018;142:e20174161. CrossRef PubMed
  30. Ofner M, Coles A, Decou ML, et al. Autism spectrum disorder among children and youth in Canada 2018. Ottawa, Canada: Public Health Agency of Canada; 2018.
  31. Schendel DE, Thorsteinsson E. Cumulative incidence of autism into adulthood for birth cohorts in Denmark, 1980–2012. JAMA 2018;320:1811–3. CrossRef PubMed
  32. Imm P, White T, Durkin MS. Assessment of racial and ethnic bias in autism spectrum disorder prevalence estimates from a US surveillance system. Autism 2019;23:1927–35. CrossRef PubMed

Top

TABLE 1. Prevalence* of autism spectrum disorder among children aged 8 years, overall and by sex — Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2016Return to your place in the text
Site Overall† Male Female Male-to-female prevalence ratio (95% CI)§
Description of surveillance area No. with ASD Total population Prevalence (95% CI) Prevalence (95% CI) Prevalence (95% CI)
Arizona Part of one county in metropolitan Phoenix† 282 17,656 16.0 (14.2–17.9) 25.4 (22.4–28.9) 6.0 (4.6–7.9) 4.2 (3.1–5.7)
Arkansas All 75 counties in Arkansas 606 40,225 15.1 (13.9–16.3) 24.3 (22.3–26.5) 5.4 (4.5–6.5) 4.5 (3.7–5.5)
Colorado Seven counties in metropolitan Denver 537 40,874 13.1 (12.1–14.3) 21.2 (19.3–23.2) 4.7 (3.9–5.8) 4.5 (3.6–5.6)
Georgia Two counties in metropolitan Atlanta 456 24,113 18.9 (17.3–20.7) 30.4 (27.5–33.6) 7.1 (5.7–8.7) 4.3 (3.4–5.4)
Maryland One county in metropolitan Baltimore 192 9,993 19.2 (16.7–22.1) 30.1 (25.8–35.2) 7.8 (5.7–10.7) 3.9 (2.7–5.5)
Minnesota Parts of two counties including Minneapolis–St. Paul 313 13,728 22.8 (20.4–25.4) 36.3 (32.1–41.0) 9.2 (7.2–11.8) 3.9 (3.0–5.2)
Missouri Two counties in metropolitan St. Louis 213 15,635 13.6 (11.9–15.6) 21.1 (18.1–24.5) 6.2 (4.6– 8.1) 3.4 (2.5–4.7)
New Jersey Four counties including metropolitan Newark 1,036 33,031 31.4 (29.5–33.3) 50.0 (46.8–53.4) 12.0 (10.4–13.8) 4.2 (3.6–4.9)
North Carolina Four counties in central North Carolina 489 19,291 25.3 (23.2–27.7) 41.2 (37.5–45.3) 8.7 (7.0–10.8) 4.7 (3.7–6.0)
Tennessee 11 counties in middle Tennessee 405 25,839 15.7 (14.2–17.3) 25.5 (22.9–28.3) 5.5 (4.4–7.0) 4.6 (3.6–6.0)
Wisconsin 10 counties in southeastern Wisconsin 579 35,034 16.5 (15.2–17.9) 26.3 (24.0–28.7) 6.3 (5.2–7.6) 4.2 (3.4–5.2)
Total 5,108 275,419 18.5 (18.0–19.1) 29.7 (28.8–30.6) 6.9 (6.5–7.4) 4.3 (4.0–4.6)

Abbreviations: ASD = autism spectrum disorder; CI = confidence interval.
* Per 1,000 children aged 8 years.
† All children are included in the total regardless of sex or race/ethnicity.
§ Wilson score 95% CIs exclude 1.0 in all sites, indicating significantly higher prevalence among males than among females.

Top

TABLE 2. Prevalence* of autism spectrum disorder among children aged 8 years, by race/ethnicity — Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2016Return to your place in the text
 Site Non-Hispanic white Non-Hispanic black Hispanic Asian/Pacific Islander† Prevalence ratios
Prevalence (95% CI) Prevalence (95% CI) Prevalence (95% CI) Prevalence (95% CI) Non-Hispanic white to non-Hispanic black (95% CI) Non-Hispanic white to Hispanic (95% CI) Non-Hispanic black to Hispanic (95% CI)
Arizona 18.8 (16.0–22.0) 12.3 (7.6–19.9) 12.4 (10.1–15.3) 11.1 (5.6–21.8) 1.5 (0.9–2.5) 1.5 (1.2–2.0)§ 1.0 (0.6–1.7)
Arkansas 16.6 (15.1–18.2) 12.1 (9.9–14.8) 9.6 (7.3–12.7) 18.6 (11.8–29.1) 1.4 (1.1–1.7)§ 1.7 (1.3–2.3)§ 1.3 (0.9–1.8)
Colorado 13.0 (11.6–14.6) 15.4 (11.5–20.7) 10.3 (8.8–12.1) 8.3 (5.2–13.3) 0.8 (0.6–1.2) 1.3 (1.0–1.5)§ 1.5 (1.1–2.1)§
Georgia 18.9 (15.9–22.5) 19.7 (17.1–22.6) 11.3 (8.9–14.4) 23.0 (17.3–30.6) 1.0 (0.8–1.2) 1.7 (1.2–2.3)§ 1.7 (1.3–2.3)§
Maryland 16.8 (13.5–20.8) 19.6 (15.5–24.7) 13.6 (7.8–23.6) 17.9 (10.5–30.4) 0.9 (0.6–1.2) 1.2 (0.7–2.2) 1.4 (0.8–2.6)
Minnesota 24.6 (20.9–28.9) 25.8 (21.2–31.5) 17.6 (12.8–24.3) 16.3 (11.7–22.6) 1.0 (0.7–1.2) 1.4 (1.0–2.0) 1.5 (1.0–2.1)§
Missouri 15.2 (12.8–18.2) 11.6 (9.2–14.6) 3.8 (1.3–11.1) 4.2 (1.4–12.4) 1.3 (1.0–1.8) 4.0 (1.4–11.9)§ 3.1 (1.0–9.2)§
New Jersey 33.4 (30.5–36.6) 26.3 (22.8–30.2) 29.8 (26.7–33.2) 26.9 (20.7–35.0) 1.3 (1.1–1.5)§ 1.1 (1.0–1.3) 0.9 (0.7–1.1)
North Carolina 23.3 (20.6–26.3) 27.9 (23.2–33.4) 19.3 (15.1–24.6) 28.2 (20.8–38.2) 0.8 (0.7–1.0) 1.2 (0.9–1.6) 1.4 (1.1–2.0)§
Tennessee 15.6 (13.8–17.6) 17.4 (14.2–21.3) 11.1 (8.1–15.1) 14.9 (8.7–25.3) 0.9 (0.7–1.1) 1.4 (1.0–2.0)§ 1.6 (1.1–2.3)§
Wisconsin 17.0 (15.3–18.9) 13.8 (11.3–16.9) 15.4 (12.6–18.7) 15.5 (10.5–22.8) 1.2 (1.0–1.5) 1.1 (0.9–1.4) 0.9 (0.7–1.2)
Total 18.5 (17.9–19.3) 18.3 (17.2–19.4) 15.4 (14.4–16.4) 17.9 (15.9–20.1) 1.0 (0.9–1.1) 1.2 (1.1–1.3)§ 1.2 (1.1–1.3)§

Abbreviation: CI = confidence interval.
* Per 1,000 children aged 8 years.
† Because of small sample size relative to other groups, prevalence ratios are not shown for Asians/Pacific Islanders. Overall, the Hispanic-to-Asian/Pacific Islander prevalence ratio is statistically significant (prevalence ratio: 0.9; Wilson score: 95% CI = 0.8–0.99), but the non-Hispanic white-to-Asian/Pacific Islander and non-Hispanic black-to-Asian/Pacific Islander prevalence ratios are not statistically different from 1.0. Counts for the numerator and denominator are available (Supplementary Table 7, [https://stacks.cdc.gov/view/cdc/85386]).
§ Wilson score 95% CIs exclude 1.0, indicating significantly different prevalence between groups.

Top

Return to your place in the textFIGURE 1. Prevalence* of autism spectrum disorder among children aged 8 years, by most recent intelligence quotient score and site — Autism and Developmental Disabilities Monitoring Network, 10 sites,† United States, 2016
Bar graph indicates estimated prevalence for 2016 of autism spectrum disorder among children aged 8 years, by most recent intelligence quotient score and site. The data source is 10 surveillance sites participating in the Autism and Developmental Disabilities Monitoring Network. Each site has prevalence for children with intelligence quotient greater than 70, less than or equal to 70, or unknown. The 10 sites are Colorado, Arkansas, Tennessee, Arizona, Wisconsin, Georgia, Maryland, Minnesota, North Carolina, and New Jersey.

Abbreviations: ADDM = Autism and Developmental Disabilities Monitoring Network; IQ = intelligence quotient.

* Per 1,000 children aged 8 years.

† Missouri is not included because it did not collect IQ information on at least 60% of children with ASD. The total numbers of children with ASD, by site: n = 537 (Colorado), n = 606 (Arkansas), n = 405 (Tennessee), n = 282 (Arizona), n = 579 (Wisconsin), n = 456 (Georgia), n = 192 (Maryland), n = 313 (Minnesota), n = 489 (North Carolina), and n = 1,036 (New Jersey).

Top

TABLE 3. Availability and distribution of intelligence quotient scores among children aged 8 years with autism spectrum disorder — Autism and Developmental Disabilities Monitoring Network, 10 sites,† United States, 2016Return to your place in the text
Site   Total no. with ASD With IQ information Cognitive level*
No. (%) IQ ≤70 (%) IQ 71–85 (%) IQ >85 (%)
Arizona 282 256 (90.8) 25.4 30.1 44.5
Arkansas 606 582 (96.0) 38.3 23.0 38.1
Colorado 537 406 (75.6) 32.0 22.2 45.8
Georgia 456 383 (84.0) 41.8 20.9 37.1
Maryland 192 124 (64.6) 34.7 25.8 38.7
Minnesota 313 283 (90.4) 24.7 19.8 54.1
New Jersey 1,036 736 (71.0) 24.6 27.9 47.4
North Carolina 489 443 (90.6) 34.1 20.8 44.9
Tennessee 405 310 (76.5) 41.0 30.3 27.7
Wisconsin 579 374 (64.6) 40.4 21.7 38.0
Total 4,895 3,897 (79.6) 33.4 24.1 42.1

Abbreviation: ASD = autism spectrum disorder; IQ = intelligence quotient.
* Levels of intellectual functioning might not always sum to exactly 100% because 15 children (three in Arkansas, one in Georgia, one in Maryland, four in Minnesota, one in North Carolina, one in New Jersey, and three in Tennessee) had evidence of IQ >70 (i.e., examiner statement) but without sufficient detail to be assigned to either the IQ 71–85 or IQ >85 categories.
† Missouri is not included because it did not collect IQ information on at least 60% of children with ASD.

Top

TABLE 4. Number and percentage of children aged 8 years with autism spectrum disorder who received a comprehensive evaluation by a qualified professional at age ≤36 months, 37–48 months, or >48 months and the median age at first evaluation, by site and selected characteristics — Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2016Return to your place in the text
Site/Characteristic Total no. of children with ASD and a linked birth certificate Youngest age when child first received a comprehensive evaluation Median age (mos) at first evaluation
≤36 mos 37–48 mos >48 mos
No. (%) No. (%) No. (%)
Site
Arizona 218 83 (38.1) 53 (24.3) 82 (37.6) 43.0
Arkansas 481 157 (32.6) 105 (21.8) 219 (45.5) 46.0
Colorado 388 186 (47.9) 60 (15.5) 142 (36.6) 37.5
Georgia 337 125 (37.1) 79 (23.4) 133 (39.5) 43.0
Maryland 172 83 (48.3) 37 (21.5) 52 (30.2) 38.0
Minnesota 246 96 (39.0) 48 (19.5) 102 (41.5) 44.5
Missouri 147 58 (39.5) 34 (23.1) 55 (37.4) 41.0
New Jersey 816 355 (43.5) 163 (20.0) 298 (36.5) 39.5
North Carolina 371 231 (62.3) 42 (11.3) 98 (26.4) 29.0
Tennessee 314 113 (36.0) 69 (22.0) 132 (42.0) 45.0
Wisconsin 491 247 (50.3) 87 (17.7) 157 (32.0) 36.0
Characteristic
Sex
  Female 730 352 (48.2) 119 (16.3) 259 (35.5) 38.0
  Male 3,251 1,382 (42.5) 658 (20.2) 1,211 (37.3) 41.0
Intellectual disability status
  IQ >70 2,038 787 (38.6) 398 (19.5) 853 (41.9) 43.0
  IQ ≤70 1,057 617 (58.4) 188 (17.8) 252 (23.8) 34.0
  IQ unknown 886 330 (37.2) 191 (21.6) 365 (41.2) 43.5
Race/Ethnicity
   Non-Hispanic white 2,063 935 (45.3) 399 (19.3) 729 (35.3) 39.0
   Non-Hispanic black 859 342 (39.8) 196 (22.8) 321 (37.4) 42.0
   Hispanic 730 313 (42.9) 129 (17.7) 288 (39.5) 40.0
Total 3,981 1,734 (43.6) 777 (19.5) 1,470 (36.9) 40.0

Abbreviations: ASD = autism spectrum disorder; IQ = intelligence quotient.

Top

TABLE 5. Median age at earliest known autism spectrum disorder diagnosis, by intellectual disability status — Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2016Return to your place in the text
Site/Characteristic No. with ASD All children with an ASD diagnosis* Children with an ASD diagnosis and IQ ≤70 Children with an ASD diagnosis and IQ >70
No. Median age (mos) at diagnosis No. Median age (mos) at diagnosis No. Median age (mos) at diagnosis
Site
Arizona 282 193 57.0 45 51.0 127 59.0
Arkansas 606 489 56.0 204 49.0 267 63.0
Colorado 537 362 48.5 105 43.0 187 54.0
Georgia 456 306 55.0 116 50.5 138 60.0
Maryland 192 150 47.5 39 37.0 60 53.0
Minnesota 313 170 56.0 40 51.5 112 60.0
Missouri 213 194 56.0 13 68.0 37 71.0
New Jersey 1,036 844 51.0 162 44.0 431 53.0
North Carolina 489 280 38.0 95 30.0 156 49.0
Tennessee 405 307 51.0 112 41.5 142 59.0
Wisconsin 579 469 49.0 128 42.0 173 59.0
Characteristic
Sex
   Female 938 649 51.0 211 43.0 281 56.0
   Male 4,170 3,115 51.0 848 45.0 1,549 57.0
Race/Ethnicity
   Non-Hispanic white 2,613 1,950 51.0 468 42.0 1,064 58.0
   Non-Hispanic black 1,070 781 53.0 295 48.0 283 57.0
   Hispanic 909 674 51.0 196 44.0 310 55.0
Total 5,108 3,764 51.0 1,059 44.0 1,830 57.0

Abbreviations: ASD = autism spectrum disorder; IQ = intelligence quotient.
* Children with unknown IQ are included in the “all children with an ASD diagnosis” category but not the IQ-specific strata.

Top

Return to your place in the textFIGURE 2. Cumulative incidence* of autism spectrum disorder diagnoses,† by age and site — Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2016
Figure consists of 11 line graphs of cumulative incidence for 2016 of autism spectrum disorder diagnoses, by age of children in months and site. The data source is 11 surveillance sites participating in the Autism and Developmental Disabilities Monitoring Network. Each site has a line for overall network incidence and site incidence. The 11 sites are Colorado, Arkansas, Tennessee, Arizona, Wisconsin, Georgia, Maryland, Minnesota, Missouri, North Carolina, and New Jersey.

Abbreviations: ADDM = Autism and Developmental Disabilities Monitoring Network; ASD = autism spectrum disorder; ICD = International Classification of Diseases.

* Per 1,000 children aged 8 years.

† These data only include the portion of ADDM Network ASD cases with a documented diagnostic statement of ASD in the record. Children counted as ADDM Network cases without a documented ASD diagnosis (i.e., does not consider special education classifications or ICD codes) are not included.

Top

Return to your place in the textFIGURE 3. Comparison of autism spectrum disorder prevalence*,† on the basis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria and community-identified§ autism spectrum disorder prevalence, by site and overall — Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2016
Figure is a comparison of autism spectrum disorder prevalence for 2016 on the basis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), criteria and community-identified autism spectrum disorder prevalence, by site. The data source is 11 surveillance sites participating in the Autism and Developmental Disabilities Monitoring Network. Each site has prevalence of community autism spectrum disorder identification compared with network identification based on DSM-5. The 11 sites are Colorado, Arkansas, Tennessee, Arizona, Wisconsin, Georgia, Maryland, Minnesota, Missouri, North Carolina, and New Jersey.

Abbreviations: ADDM = Autism and Developmental Disabilities Monitoring Network; ASD = autism spectrum disorder; DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; ICD = International Classification of Diseases.

* Per 1,000 children aged 8 years.

† The dots represent prevalence estimates and the vertical lines bounded by bars represent the corresponding 95% confidence intervals.

§ Children are considered to be identified as having ASD by the community if they have an autism diagnosis stated in an evaluation, have been determined to meet autism eligibility in special education, or have been assigned an autism ICD code. Missouri, Colorado, and Wisconsin had limited access to information from educational records.

Top


Suggested citation for this article: Maenner MJ, Shaw KA, Baio J, et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016. MMWR Surveill Summ 2020;69(No. SS-4):1–12. DOI: http://dx.doi.org/10.15585/mmwr.ss6904a1.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

View Page In: Learn the Signs. Act Early MMWR Article PDF